1 unchanged sentence
Rule 10b5-1 Trading Plans
−Removed: During the quarter ended September 30, 2025, none of our directors or executive officers adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K).
−Removed: Credit Agreement, dated July 31, 2025, among Myriad Genetics, Inc., the lenders from time to time party thereto, and Orbimed Royalty and Credit Opportunities IV, LP, as initial lender and administrative agent (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, File No.
−Removed: 000-26642, filed with the SEC on July 31, 2025).
−Removed: Pledge and Security Agreement, dated July 31, 2025, among Myriad Genetics, Inc., each of the other Guarantors and Orbimed Royalty and Credit Opportunities IV, LP, as administrative agent for the secured parties (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K, File No.
−Removed: 000-26642, filed with the SEC on July 31, 2025).
−Removed: Separation Agreement and Release of Claims, dated October 1, 2025, by and between the Com pany and Scott J.
−Removed: Leffler (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, File No.
−Removed: 000-26642, filed with the SEC on October 7, 2025 ).
−Removed: Executive Employment Agreement, dated August 1 4, 2025, by and between the Company and Ben jamin R.
+Added: During the quarter ended March 31, 2026, none of our directors or executive officers adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K).
+Added: First Amendment to Credit Agreement, dated January 5, 2026, among Myriad Genetics, Inc., the lenders party thereto and Orbimed Royalty & Credit Opportunities IV, LP, as administrative agent (incorporated by reference to Exhibit 10.26 to the Company's Annual Report on Form 10-K, File No.
+Added: 000-26642, filed with the SEC on February 24, 2026).
31.1 Certification of Principal Executive Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.
−Removed: 31.2 Certification of Prin cipal Financial Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.
+Added: 31.2 Certification of Principal Financial Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.
Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
5 unchanged sentences
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document.
−Removed: 104 The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 has been formatted in Inline XBRL.
−Removed: + Management contract or compensatory plan or arrangement.
+Added: 104 The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 has been formatted in Inline XBRL.
* The Certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Myriad Genetics, Inc.
2 unchanged sentences
MYRIAD GENETICS, INC.
−Removed: November 4, 2025 By:
+Added: May 6, 2026 By:
/s/ Samraat S.
1 unchanged sentence
(Principal executive officer)
−Removed: November 4, 2025 By:
+Added: May 6, 2026 By:
/s/ Benjamin R.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.